febuxostat tablets 40 mg
FEBUXOSTAT (febuxostat tablets 40 mg) is xanthine oxidase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 4h ago
Xanthine Oxidase Inhibitors
Xanthine Oxidase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Tigulixostat (IBI128) vs Febuxostat in Gout
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo